Effects of Orlistat on Fat‐Soluble Vitamins in Obese Adolescents

Study Objectives. To determine whether orlistat causes fat‐soluble vitamin deficiencies in African‐American and Caucasian adolescents.

[1]  M. Nestle.  Ethical dilemmas in choosing a healthful diet: vote with your fork! , 2000, Proceedings of the Nutrition Society.

[2]  M. Traber,et al.  Measurement of lipid-soluble vitamins-further adjustment needed? , 2000, The Lancet.

[3]  Shumei S. Guo,et al.  CDC growth charts; United States , 2000 .

[4]  G. Williams,et al.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor , 2000, International Journal of Obesity.

[5]  C. Lucas,et al.  Orlistat in the long-term treatment of obesity in primary care settings. , 2000, Archives of family medicine.

[6]  S. Booth,et al.  Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults. , 1999, The American journal of clinical nutrition.

[7]  K. Fujioka,et al.  Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. , 1999, The American journal of clinical nutrition.

[8]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[9]  J. Zhi,et al.  Long‐Term Systemic Exposure of Orlistat, a Lipase Inhibitor, and Its Metabolites in Obese Patients , 1999, Journal of clinical pharmacology.

[10]  C. Gundberg,et al.  Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. , 1998, The Journal of clinical endocrinology and metabolism.

[11]  Roy A Kaplan,et al.  Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.

[12]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[13]  S. Booth,et al.  Dietary intake and adequacy of vitamin K. , 1998, The Journal of nutrition.

[14]  L. V. Van Gaal,et al.  Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study , 1998, European Journal of Clinical Pharmacology.

[15]  J. Whitehead,et al.  A one-year trial to assess the value of orlistat in the management of obesity. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[16]  R. Guerciolini.  Mode of action of orlistat. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[17]  J. Zhi,et al.  Metabolic Profiles of Minimally Absorbed Orlistat in Obese/Overweight Volunteers , 1996, Journal of clinical pharmacology.

[18]  J. Zhi,et al.  The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Absorption of Vitamins A and E in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[19]  J. Zhi,et al.  The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Pharmacokinetics of β‐Carotene in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[20]  P Dempster,et al.  A new air displacement method for the determination of human body composition. , 1995, Medicine and science in sports and exercise.

[21]  M. Drent,et al.  First clinical studies with orlistat: a short review. , 1995, Obesity research.

[22]  J. Zhi,et al.  Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers , 1995, Journal of clinical pharmacology.

[23]  M. Holick,et al.  Compensation for the interracial variance in the cutaneous synthesis of vitamin D. , 1995, The Journal of laboratory and clinical medicine.

[24]  B. Hollis,et al.  Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. , 1993, Clinical chemistry.

[25]  B. Hollis,et al.  Racial pigmentation and the cutaneous synthesis of vitamin D. , 1991, Archives of dermatology.

[26]  A. Whorton,et al.  Regulation of endothelin-mediated calcium mobilization in vascular smooth muscle cells by isoproterenol. , 1991, The American journal of physiology.

[27]  T. D. de Bruin,et al.  Postprandial decrease in HDL cholesterol and HDL apo A-I in normal subjects in relation to triglyceride metabolism. , 1991, The American journal of physiology.

[28]  G. Peck,et al.  Liquid-chromatographic assay for retinol (vitamin A) and retinol analogs in therapeutic trials. , 1982, Clinical chemistry.

[29]  J. Adams,et al.  INCREASED SKIN PIGMENT REDUCES THE CAPACITY OF SKIN TO SYNTHESISE VITAMIN D3 , 1982, The Lancet.

[30]  Paul Trinder.  Oxidase Determination of Plasma Cholesterol as Cholest-4-En-3-One Using Iso-Octane Extraction , 1981, Annals of clinical biochemistry.

[31]  C. Fraser,et al.  Assessment of colorimetric enzymatic determination of triglyceride, by manual and centrifugal analyzer techniques, and comparison with a CDC standardized method. , 1981, Clinical biochemistry.

[32]  J. A. Spirito,et al.  Modification of Lofland's colorimetric semiautomated serum triglyceride determination, assessed by an enzymatic glycerol determination. , 1968, Journal of lipid research.

[33]  S. Tonstad,et al.  The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia , 2004, European Journal of Clinical Pharmacology.

[34]  T. Mhlanga,et al.  An investigation into a possible relationship between vitamin D, parathyroid hormone, calcium and magnesium in a normally pigmented and an albino rural black population in the Northern Province of South Africa. , 2000, BioFactors.

[35]  M. Carroll,et al.  Overweight and obesity in the United States: prevalence and trends, 1960–1994 , 1998, International Journal of Obesity.

[36]  L. V. Van Gaal,et al.  Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. , 1998, European journal of clinical pharmacology.

[37]  A. Rissanen,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. , 1998, Lancet.

[38]  J. Sadowski,et al.  Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. , 1997, Methods in enzymology.

[39]  Update: prevalence of overweight among children, adolescents, and adults--United States, 1988-1994. , 1997, MMWR. Morbidity and mortality weekly report.

[40]  B. Specker,et al.  Vitamin D in infancy and childhood: factors determining vitamin D status. , 1986, Advances in pediatrics.